{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T14:58:09Z","timestamp":1768748289028,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","award":["GGP20097"],"award-info":[{"award-number":["GGP20097"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["28892"],"award-info":[{"award-number":["28892"]}],"id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","award":["23000"],"award-info":[{"award-number":["23000"]}],"id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA 577888"],"award-info":[{"award-number":["MDA 577888"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["577888"],"award-info":[{"award-number":["577888"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bcp.2025.116779","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T23:56:33Z","timestamp":1737762993000},"page":"116779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The novel use of the CFTR corrector C17 in muscular dystrophy: pharmacological profile and in vivo efficacy"],"prefix":"10.1016","volume":"233","author":[{"given":"Alberto","family":"Benetollo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Parrasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Scano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Biasutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Nogara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Blaauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dalla Barba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Caccin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Carotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Parolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eylem Emek","family":"Aky\u00fcrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Sacchetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorianna","family":"Sandon\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116779_b0005","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.nmd.2018.05.007","article-title":"229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017","volume":"28","author":"Straub","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bcp.2025.116779_b0010","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1017\/S1462399409001203","article-title":"Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects","volume":"11","author":"Sandona","year":"2009","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.bcp.2025.116779_b0015","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.nmd.2021.07.014","article-title":"Sarcoglycanopathies: an update","volume":"31","author":"Vainzof","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bcp.2025.116779_b0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1212\/WNL.0000000000000892","volume":"83","author":"Narayanaswami","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2025.116779_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2024.102459","article-title":"Advanced therapeutic approaches in sarcoglycanopathies","volume":"76","author":"Scano","year":"2024","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116779_b0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/21678707.2017.1307731","article-title":"Emerging therapeutic strategies for sarcoglycanopathy","volume":"5","author":"Carotti","year":"2017","journal-title":"Expert Opin. Orphan D"},{"key":"10.1016\/j.bcp.2025.116779_b0035","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/hmg\/ddn029","article-title":"Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation","volume":"17","author":"Bartoli","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.116779_b0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2353\/ajpath.2008.071146","article-title":"Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan","volume":"173","author":"Gastaldello","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2025.116779_b0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/humu.21659","article-title":"Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications","volume":"33","author":"Soheili","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bcp.2025.116779_b0050","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1093\/hmg\/ddu088","article-title":"Unveiling the degradative route of the V247M \u03b1-sarcoglycan mutant responsible for LGMD-2D","volume":"23","author":"Bianchini","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.116779_b0055","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Lopes-Pacheco","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bcp.2025.116779_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051813","article-title":"Combined use of CFTR correctors in LGMD2D myotubes improves sarcoglycan complex recovery","volume":"21","author":"Carotti","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116779_b0065","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/hmg\/ddy013","article-title":"Repairing folding-defective alpha-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D","volume":"27","author":"Carotti","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.116779_b0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/hmg\/ddab260","article-title":"CFTR corrector C17 is effective in muscular dystrophy, in vivo proof of concept in LGMDR3","volume":"31","author":"Scano","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.116779_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13321-018-0324-5","article-title":"BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification","volume":"11","author":"Djoumbou-Feunang","year":"2019","journal-title":"J. Cheminf."},{"key":"10.1016\/j.bcp.2025.116779_b0080","doi-asserted-by":"crossref","first-page":"W115","DOI":"10.1093\/nar\/gkac313","article-title":"BioTransformer 3.0-a web server for accurately predicting metabolic transformation products","volume":"50","author":"Wishart","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.116779_b0085","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920007782798207","article-title":"The conduct of drug metabolism studies considered good practice (II): In vitro experiments","volume":"8","author":"Jia","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2025.116779_b0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: Should it be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bcp.2025.116779_b0095","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1021\/acs.analchem.9b00310","article-title":"Controlling preanalytical process in high-coverage quantitative metabolomics: spot-sample collection for mouse urine and fecal metabolome profiling","volume":"91","author":"Chen","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.bcp.2025.116779_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/cpph.16","article-title":"Stability of drugs, drug candidates, and metabolites in blood and plasma","volume":"75","author":"Reed","year":"2016","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.bcp.2025.116779_b0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/cpt.548","article-title":"Can cystic fibrosis patients finally catch a breath with lumacaftor\/ivacaftor?","volume":"101","author":"Schneider","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.116779_b0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0041-008X(03)00128-5","article-title":"An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons","volume":"189","author":"Brandon","year":"2003","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116779_b0115","series-title":"Physiology, Gastrointestinal","author":"Ogobuiro","year":"2024"},{"key":"10.1016\/j.bcp.2025.116779_b0120","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1089\/hum.2019.006","article-title":"Gene delivery for limb-girdle muscular dystrophy type 2D by isolated limb infusion","volume":"30","author":"Mendell","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcp.2025.116779_b0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8416","article-title":"Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy","volume":"13","author":"Careccia","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2025.116779_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010089","article-title":"P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy","volume":"15","author":"Raffaghello","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bcp.2025.116779_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102629","article-title":"Nintedanib reduces muscle fibrosis and improves muscle function of the alpha-sarcoglycan-deficient mice","volume":"10","author":"Alonso-Perez","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2025.116779_b0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.116779_b0145","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.116779_b0150","article-title":"CFTR Modulators: Does one dose fit all?","author":"Meer","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bcp.2025.116779_b0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bcp.2011.11.014","article-title":"Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump","volume":"83","author":"Loo","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116779_b0160","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1021\/bi4008758","article-title":"Bithiazole correctors rescue CFTR mutants by two different mechanisms","volume":"52","author":"Loo","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2025.116779_b0165","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jhep.2016.02.001","article-title":"Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis","volume":"64","author":"van der Woerd","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2025.116779_b0170","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/hmg\/ddy011","article-title":"Functional rescue of misfolding ABCA3 mutations by small molecular correctors","volume":"27","author":"Kinting","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2025.116779_b0175","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/liv.14839","article-title":"Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants","volume":"41","author":"Ben Saad","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.bcp.2025.116779_b0180","doi-asserted-by":"crossref","first-page":"R197","DOI":"10.1016\/S0960-9822(02)00748-0","article-title":"Cadherin-like domains in alpha-dystroglycan, alpha\/epsilon-sarcoglycan and yeast and bacterial proteins","volume":"12","author":"Dickens","year":"2002","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2025.116779_b0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biocel.2014.02.004","article-title":"CFTR structure and cystic fibrosis","volume":"52","author":"Cant","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2025.116779_b0190","unstructured":"ChemSketch, version 2022.1.2, Advanced Chemistry Development, Inc. (ACD\/Labs), Toronto, ON, Canada, www.acdlabs.com."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T12:13:03Z","timestamp":1745842383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"alternative-id":["S0006295225000413"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116779","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel use of the CFTR corrector C17 in muscular dystrophy: pharmacological profile and in vivo efficacy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116779"}}